Tags : Knight Therapeutics

PharmaShots Weekly Snapshot (November 18-22, 2019)

1.  Lupin Launches Smart Device for Metered-Dose Inhalers to Support Treatment of Respiratory Diseases in India Published: Nov 22, 2019 | Tags: Lupin, Launches, Smart Device, Metered-Dose Inhalers, Support, Treatment, Respiratory Diseases, India 2. BioMarin Reports Submission of MAA to EMA for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A Published: Nov 21, 2019 | Tags: BioMarin, […]Read More

Knight Therapeutics Signs an Exclusive License Agreement with Onconova for

Shots: Onconova to receive $25.55M as clinical, regulatory and commercialization milestones and royalties on sales of Rigosertib. Knight therapeutics to receive exclusive rights to commercialize Rigosertib in Canada If approved, Rigosertib would meet the unmet medical need of the patients suffering from myelodysplastic syndromes and is currently being evaluated in P-III INSPIRE study assessing Rigosertib […]Read More

Knight Therapeutics’ Nerlynx (neratinib) Receives Health Canada Approval as Extended

Shots: The marketing authorization is based on P-III ExteNET study results assessing Nerlynx following adjuvant trastuzumab therapy vs PBO in 2,840 patients with early-stage HER2-positive breast cancer within two of completing trastuzumab-based adjuvant therapy The P-III ExteNET study resulted in a 51% reduction in risk of diseases recurrence in patients @2yrs. with invasive disease-free survival […]Read More